Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.49 |
| ▸ | BLM | P54132 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | APEX1 | P27695 | 1/20 | 0.49 |
| ▸ | PI4KA | P42356 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.49 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.49 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.49 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1001853 | 0.81 | CYP2C19 (0.48) | CYP2C19NFKB1BLMTP53CYP2C9 | |
| SCHEMBL18571622 | 0.80 | ALDH1A1 (0.50) | MAPK1ALDH1A1CYP1A2ADORA1 | |
| SCHEMBL22799584 | 0.80 | ALDH1A1 (0.50) | MAPK1ALDH1A1CYP1A2ADORA1 | |
| SCHEMBL17009435 | 0.80 | CYP2C19 (0.54) | CYP2C19NFKB1BLMTP53CYP2C9 | |
| SCHEMBL20322870 | 0.78 | CYP2C19 (0.56) | CYP2C19NFKB1BLMTP53CYP2C9 | |
| SCHEMBL889648 | 0.77 | HIF1A (0.49) | — | |
| SCHEMBL889682 | 0.77 | HIF1A (0.59) | — | |
| SCHEMBL20323065 | 0.76 | CYP2C19 (0.52) | CYP2C19NFKB1BLMTP53CYP2C9 | |
| SCHEMBL1002031 | 0.76 | CYP2C19 (0.49) | CYP2C19NFKB1BLMTP53CYP2C9 | |
| SCHEMBL12775475 | 0.75 | CYP2C19 (0.67) | CYP2C19NFKB1BLMTP53CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10851109-B2 | Compositions and methods of using the same for treatment of neurodegenerative and mitochondrial disease | MITOKININ LLC (US) | 2020-12-01 | — | — | US | disclosed |
| US-10167286-B2 | Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease | MITOKININ, INC. (US) | 2019-01-01 | — | — | US | disclosed |
| US-20170190704-A1 | COMPOSITIONS AND METHODS USING THE SAME FOR TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE | Mitokinin, LLC (US) | 2017-07-06 | — | — | US | disclosed |
| US-20170190704-A1 | COMPOSITIONS AND METHODS USING THE SAME FOR TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE | Mitokinin, LLC (US) | 2017-07-06 | — | — | US | disclosed |
| WO-2015123365-A1 | COMPOSITIONS AND METHODS USING THE SAME FOR TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE | MITOKININ LLC (US) | 2015-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10167286-B2 | Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease | NLN, NME4, COQ8A | CYP2C19 1290/4885NFKB1 2656/4885BLM 576/4885 |
| US-10851109-B2 | Compositions and methods of using the same for treatment of neurodegenerative and mitochondrial disease | NLN, NME4, COQ8A | CYP2C19 1436/4885NFKB1 2906/4885BLM 759/4885 |
| US-20170190704-A1 | COMPOSITIONS AND METHODS USING THE SAME FOR TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE | NLN, HAGH, MT-ND2 | CYP2C19 4071/4885NFKB1 3815/4885BLM 1782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.